Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Matthew A Lunning

Showing results (1-10 of 62) with videos related to

Pageof 7
Sort By:
Journal of Oncology Practice|October 11, 2019
Extranodal NK/T-Cell Lymphoma, Nasal Type: Shrouded No MoreMatthew A Lunning
Oncology (Williston Park, N.Y.)|August 19, 2015
Treatment of Peripheral T-Cell Lymphoma: Many Shades of GrayMatthew A Lunning
Leukemia & Lymphoma|March 23, 2013
Brentuximab vedotin: the science of common senseMatthew A Lunning, Anas Younes
Current Treatment Options in Oncology|April 10, 2013
Treatment of peripheral T-cell lymphoma: are we data driven or driving the data?Matthew A Lunning, Steven Horwitz
Blood|December 10, 2020
Checkpoint inhibition in ENKTL: Kno_le_ge G_psRadowan Elnair, Matthew A Lunning
Oncology (Williston Park, N.Y.)|November 7, 2014
The place of transplantation in mantle cell lymphomaMatthew A Lunning, James O Armitage
Blood|January 25, 2017
Angioimmunoblastic T-cell lymphoma: the many-faced lymphomaMatthew A Lunning, Julie M Vose
Haematologica|July 2, 2015
Rituximab maintenance therapy in diffuse large B-cell lymphoma: is XY the most important variable?Matthew A Lunning, James O Armitage
Blood|November 17, 2018
Do you know TAFRO?Matthew A Lunning, James O Armitage
Oncology (Williston Park, N.Y.)|May 21, 2014
Directing treatment by molecular subtype in diffuse large B-cell lymphoma: ready for primetime?Matthew A Lunning, James O Armitage
Pageof 7

Showing results (1-10 of 62) with videos related to

Sort By:
Pageof 7
Journal of Oncology Practice|October 11, 2019
Extranodal NK/T-Cell Lymphoma, Nasal Type: Shrouded No MoreMatthew A Lunning
Oncology (Williston Park, N.Y.)|August 19, 2015
Treatment of Peripheral T-Cell Lymphoma: Many Shades of GrayMatthew A Lunning
Leukemia & Lymphoma|March 23, 2013
Brentuximab vedotin: the science of common senseMatthew A Lunning, Anas Younes
Current Treatment Options in Oncology|April 10, 2013
Treatment of peripheral T-cell lymphoma: are we data driven or driving the data?Matthew A Lunning, Steven Horwitz
Blood|December 10, 2020
Checkpoint inhibition in ENKTL: Kno_le_ge G_psRadowan Elnair, Matthew A Lunning
Oncology (Williston Park, N.Y.)|November 7, 2014
The place of transplantation in mantle cell lymphomaMatthew A Lunning, James O Armitage
Blood|January 25, 2017
Angioimmunoblastic T-cell lymphoma: the many-faced lymphomaMatthew A Lunning, Julie M Vose
Haematologica|July 2, 2015
Rituximab maintenance therapy in diffuse large B-cell lymphoma: is XY the most important variable?Matthew A Lunning, James O Armitage
Blood|November 17, 2018
Do you know TAFRO?Matthew A Lunning, James O Armitage
Oncology (Williston Park, N.Y.)|May 21, 2014
Directing treatment by molecular subtype in diffuse large B-cell lymphoma: ready for primetime?Matthew A Lunning, James O Armitage
Pageof 7